SCHEMBL2923164

SCHEMBL2923164

Cc1ccc(-c2nc3cc(O)ccc3s2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 10/20 0.71
MAPT P10636 6/20 0.63
SMN1; SMN2 Q16637 3/20 0.63
TP53 P04637 2/20 0.63
KDM4E B2RXH2 4/20 0.57
NPC1 O15118 4/20 0.57
GAA P10253 4/20 0.57
RAB9A P51151 4/20 0.57
ALDH1A1 P00352 3/20 0.57
GLA P06280 3/20 0.57
LMNA P02545 1/20 0.57
SULT1A1 P50225 3/20 0.55
ILK Q13418 1/20 0.53
NFKB1 P19838 2/20 0.53
NFKB2 Q00653 2/20 0.53
RELA Q04206 2/20 0.53
MEN1 O00255 1/20 0.53
POLB P06746 1/20 0.53
GFER P55789 1/20 0.53
KMT2A Q03164 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2922465 0.87 APP (0.72) APPMAPTSMN1; SMN2TP53KDM4E
SCHEMBL14878460 0.86 MAPT (0.81) APPMAPTSMN1; SMN2TP53KDM4E
SCHEMBL12408909 0.84 MAPT (0.84) APPMAPTSMN1; SMN2TP53KDM4E
SCHEMBL13806234 0.84 APP (0.77) APPMAPTSMN1; SMN2TP53KDM4E
SCHEMBL13391563 0.84 APP (0.77) APPMAPTSMN1; SMN2TP53KDM4E
SCHEMBL2914054 0.83 APP (0.66) APPMAPTSMN1; SMN2TP53KDM4E
SCHEMBL12422099 0.83 MAPT (0.62) APPMAPTSMN1; SMN2TP53KDM4E
SCHEMBL14205633 0.83 APP (0.65) APPMAPTSMN1; SMN2TP53KDM4E
SCHEMBL2244143 0.81 APP (0.72) APPMAPTSMN1; SMN2TP53KDM4E
SCHEMBL2242138 0.81 MAPT (0.82) APPMAPTSMN1; SMN2TP53KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2222160-B1 HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR PHARMAXIS LTD (AU) 2015-03-18 EP disclosed
US-8426587-B2 Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor PHARMAXIS LTD. (AU) 2013-04-23 US disclosed
US-20100298330-A1 HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR PHARMAXIS LTD. (AU) 2010-11-25 US disclosed
EP-2222160-A2 HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR Pharmaxis Ltd. (AU) 2010-09-01 EP disclosed
WO-2009066152-A2 HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR PHARMAXIS LTD. (US) 2009-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298330-A1 HALOALLYLAMINE INHIBITORS OF SSAO/VAP-1 AND USES THEREFOR VAPA, SLC6A11, VAPB APP 1634/4885MAPT 2307/4885SMN1; SMN2 1608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.